0001570562-24-000030.txt : 20240223
0001570562-24-000030.hdr.sgml : 20240223
20240223202747
ACCESSION NUMBER: 0001570562-24-000030
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240221
FILED AS OF DATE: 20240223
DATE AS OF CHANGE: 20240223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Avelar Rui
CENTRAL INDEX KEY: 0001432063
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38381
FILM NUMBER: 24673300
MAIL ADDRESS:
STREET 1: 1618 STATION STREET
CITY: VANCOUVER
STATE: A1
ZIP: V6A 1B6
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Evolus, Inc.
CENTRAL INDEX KEY: 0001570562
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 461385614
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 520 NEWPORT CENTER DRIVE
STREET 2: SUITE 1200
CITY: NEWPORT BEACH
STATE: CA
ZIP: 92660
BUSINESS PHONE: (949) 284-4555
MAIL ADDRESS:
STREET 1: 520 NEWPORT CENTER DRIVE
STREET 2: SUITE 1200
CITY: NEWPORT BEACH
STATE: CA
ZIP: 92660
4
1
wk-form4_1708738054.xml
FORM 4
X0508
4
2024-02-21
0
0001570562
Evolus, Inc.
EOLS
0001432063
Avelar Rui
520 NEWPORT CENTER DR.
SUITE 1200
NEWPORT BEACH
CA
92660
0
1
0
0
See Remarks
1
Common Stock
2024-02-21
4
A
0
13115
0
A
401712
D
Common Stock
2024-02-22
4
S
0
1821
13.0812
D
399891
D
Represents shares issuable on settlement of performance restricted stock units ("PSUs") granted to the reporting person in January 2023. The Issuer's Compensation Committee certified that the reporting person had achieved the set corporate development goal as of December 20, 2023. One-third of the PSU (4,372 shares) was delivered on February 21, 2024 after certification of the milestone being achieved. The remaining two-thirds will vest annually on the anniversary of December 20, 2023 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the PSUs.
Chief Medical Officer & Head of Research and Development
/s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar
2024-02-23